Audit: QRS - sh-Polypeptide-7 for Hair Regrowth

Audit conducted on 28/09/2026 07:57 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, tiers, gates, markers and cadence each trace to ER text (Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions, Monitoring)
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious phrasing carried: “if absorbed”, “direction only”, “No established target”, “No hair-specific target”, “(relative contraindication)”
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Topical retinoids surfaced as a contraindication because the ER labels them “Relative contraindication”
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	KeraFactor, KeraLase, HydraScalp, Keravive and WADA all appear in the ER for the same facts; no PMIDs or NCT IDs
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Specialist terms are glossed (trichoscopy, secretagogues, photosensitizing, acromegaly, IGF-1, TSH, CBC, PRP, GABA, NSAIDs, WADA)
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede frames the verdict for “hair-focused adults willing to invest effort”
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template data-qrs-var spans present, incl. page_title; marker_# and qualitative_item_# repeated for 9 markers / 5 items
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website= spans, template comments and CSS are identical to the template

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding a QRS field is empty; the empty High/Medium benefit and risk tiers are handled by 12.5/13.5 (display: none)
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed relative to the ER (interaction consequences/mitigations stripped; benefits/risks reduced to headings); nothing is extended

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment sits on line 2 directly after <!doctype html>
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted (“00:02”), which contains a colon
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“sh-Polypeptide-7 for Hair Regrowth - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0928-0710 → 09/28/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens: “a lab-made copy of human growth hormone sold as a cosmetic ingredient in scalp serums for thinning hair”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	Exactly 70 words
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 8 ER “Populations who should avoid” items plus the ER relative contraindication for topical retinoids with devices
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within the past 6 months”, “(laser- or needle-assisted protocols)”, “(relative contraindication)” preserved
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER contraindication bullets use no ranking notation inside parentheses
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –>	N/A	Section is populated (9 items)

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ER interactions except isotretinoin/retinoids (listed as contraindications) and the “Compatible; no known interaction” 5-alpha-reductase inhibitor entry
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug and supplement lists and the needle-/laser-assisted delivery qualifiers preserved
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER interaction bullets use no ranking notation inside parentheses
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –>	N/A	Section is populated (9 items)

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Home serum, KeraLase laser protocol and HydraScalp/Keravive protocol, matching the ER’s three bold-labeled protocols
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol names three distinct delivery protocols; all three sets used
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Hair density/diameter (principal Low benefit) first, then sponsor-reported fullness, then scalp symptoms (Not Central)
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three distinct time-to-effect aspects; all three sets used
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information (Practical Considerations, Monitoring, Expected Benefits)

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_medium spans carry style=”display: none”

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_medium spans carry style=”display: none”

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 6 table biomarkers plus CBC, C-reactive protein and free thyroxine named in the ER Monitoring section
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 5 ER qualitative markers listed verbatim

Issues 28/09/2026 07:57

Pass rate 100.00%. No issues found.

Issues 28/09/2026 07:53

1. 1.3 — IGF-1 optional qualifier dropped: The Monitoring table (QRS lines 662-669) presents IGF-1 as a routine marker, whereas the ER marks it “optional” and to be tested only “where growth hormone excess or deficiency is suspected” (ER lines 313, 324).

Fixes 28/09/2026 07:53

1. 1.3 — IGF-1 optional qualifier restored: Changed marker_6_why from “Flags growth hormone excess or deficiency” to “Optional; where growth hormone excess or deficiency is suspected”, matching ER lines 313 and 324.

Issues 28/09/2026 07:51

1. 2.7 — Photosensitizing drugs left unexplained: The Key Interactions item “Photosensitizing drugs (doxycycline, hydrochlorothiazide)” (QRS line 560) drops the ER’s plain-language gloss “drugs that make skin more sensitive to light” (ER line 230), leaving a technical term unexplained.

Fixes 28/09/2026 07:51

1. 2.7 — Photosensitizing drugs gloss restored: Changed “Photosensitizing drugs (doxycycline, hydrochlorothiazide)” to “Photosensitizing drugs (drugs that make skin more sensitive to light; doxycycline, hydrochlorothiazide)” in Key Interactions, matching the ER wording.

Issues 28/09/2026 07:47

1. 4.2 / 4.3 — Interaction label gloss paraphrased: Key Interactions item 1 (line 558) renders the ER bold-label gloss “drugs that trigger natural growth hormone release” as “growth hormone–release triggers”, a paraphrase rather than the verbatim or trimmed ER label.
2. 4.5 — Exceeds one A4 page: Nine multi-line interaction items (lines 558–566), nine contraindications, a 9-row monitoring table, and five qualitative items stack to roughly 1.4 A4 pages; gate items were not condensed to the page budget.

Fixes 28/09/2026 07:47

1. 4.2 / 4.3 — Interaction label gloss restored: Replaced “growth hormone–release triggers” with the ER’s verbatim gloss “drugs that trigger natural growth hormone release” in Key Interactions item 1.
2. 4.5 — Condensed toward one page: Trimmed the photosensitizing-drug gloss to its example drug list and shortened the CBC and C-reactive protein “Why” cells (“Paired with ferritin”, “Inflammation raises ferritin”) to reduce wrapped lines.

Issues 28/09/2026 07:43

1. 2.7 — Unexplained “photosensitizing” jargon: The Key Interactions item “Photosensitizing drugs (doxycycline, hydrochlorothiazide) with laser or red-light protocols: monitor” (QRS line 560) leaves the technical term unexplained, although the ER glosses it as “drugs that make skin more sensitive to light” (ER line 230) and all other drug classes on the sheet carry a plain-language gloss.

Fixes 28/09/2026 07:43

1. 2.7 — Photosensitizing drugs gloss added: Changed “Photosensitizing drugs (doxycycline, hydrochlorothiazide)” to “Photosensitizing drugs (drugs that make skin more sensitive to light; doxycycline, hydrochlorothiazide)” using the ER’s own gloss.

Issues 28/09/2026 07:39

1. 9.4 — Explanatory glosses in interactions: Caution items carry elaborations beyond the key fact, e.g. “blood thinners that slow clotting” (line 559), “drugs that make skin more sensitive to light” (line 560), “a calming brain messenger” (line 564), “a concentrate of the person’s own platelets” (line 566) and “drugs that trigger natural growth hormone release” (line 558).

Fixes 28/09/2026 07:39

1. 9.4 — Explanatory glosses in interactions: Trimmed elaborations from caution items: “drugs that trigger natural growth hormone release” → “growth hormone–release triggers”, “blood thinners that slow clotting” → “blood thinners”, removed “drugs that make skin more sensitive to light”, “a calming brain messenger” and “a concentrate of the person’s own platelets”; example drug lists kept.

Issues 28/09/2026 07:36

1. 4.2 / 4.3 — Key Interaction labels merged/trimmed: Lines 561 and 564 merge two ER bold-labelled interactions each into one invented label, and lines 547, 562 and 563 abbreviate the ER labels (dropping “vitamin A–derived skin drugs”, “(over-the-counter)” and “, a calming brain messenger”; line 564 also trims the PRP definition).

Fixes 28/09/2026 07:36

1. 4.2 / 4.3 — Key Interaction labels restored: Split the merged “Aspirin, NSAIDs … and blood-thinning supplements” and “Other peptide … and other interventions” items into separate items carrying the ER bold labels verbatim, and restored the trimmed label text “(over-the-counter)”, “, a calming brain messenger”, the full PRP definition, and “vitamin A–derived skin drugs” in the topical retinoids contraindication.

Issues 28/09/2026 07:32

1. 2.7 — Jargon without ER glosses: The Key Interactions gate drops the ER’s plain-language explanations for “Anticoagulants and antiplatelet drugs” (line 559) and “Photosensitizing drugs” (line 560), and time_3_sub (line 511) uses the unexplained term “single-arm study”.

Fixes 28/09/2026 07:32

1. 2.7 — Restored ER plain-language glosses: Added the ER’s explanations “blood thinners that slow clotting” and “drugs that make skin more sensitive to light” to the anticoagulant and photosensitizing-drug interaction items, and replaced “single-arm study” in time_3_sub with “study without a comparison group”.

Issues 28/09/2026 07:29

1. 4.5 — Sheet exceeds one A4 page: The Key Interactions gate (lines 557-567) carries 9 long items with explanatory glosses (~25 wrapped lines in a half-width column), which together with 9 Contraindications and a 9-row Monitoring table pushes the sheet past one A4 page; the densest sections were not condensed.

Fixes 28/09/2026 07:29

1. 4.5 — Condensed Key Interactions gate: Stripped explanatory glosses from the anticoagulant and photosensitizer items and “(over-the-counter)” from minoxidil, merged aspirin/NSAIDs with blood-thinning supplements and other peptide serums with other interventions (same action level), cutting the gate from 9 to 7 items while keeping all example drug lists and qualifiers.

Issues 28/09/2026 07:25

1. 4.5 — Content exceeds one A4 page: With ≈5,000 visible characters (9 contraindications, 9 long interaction items, a 9-row monitoring table, 5 qualitative items and a 70-word lede), the sheet renders to roughly 1.7 A4 pages; free-text fields such as action_1_sub (line 450), time_1_sub (line 489), time_3_sub (line 511), marker_6_why (line 668) and monitoring_cadence (line 708) are not condensed to the per-section budget.

Fixes 28/09/2026 07:25

1. 4.5 — Condensed free-text fields: Shortened action_1_sub (“Massaged in, not rinsed; patent range 0.00043–0.00243% by product weight”), time_1_sub (“Judgments before 12 weeks rest on little information”), time_3_sub (“Sponsor’s single-arm study; direction only”), marker_6_why (“Flags growth hormone excess or deficiency”) and the cadence opener (“Baseline;”). Trimmed the secondary glosses after GABA and PRP in Key Interactions, keeping the acronym expansions and all example lists.

Issues 28/09/2026 07:21

1. 2.7 — Unglossed jargon in gates: “Anticoagulants and antiplatelet drugs” (line 559), “Photosensitizing drugs” (line 560) and “Acromegaly” (line 544) appear without the plain-language explanations the ER provides (“blood thinners that slow clotting”, “drugs that make skin more sensitive to light”, adult growth hormone excess).
2. 4.2 — ER bold labels not verbatim: The Key Interactions items for anticoagulants (line 559), photosensitizing drugs (line 560), growth hormone–releasing supplements (GABA gloss, line 564) and other interventions (PRP gloss, line 566) drop or cut the glosses contained in the ER’s bold labels, while other items keep theirs.

Fixes 28/09/2026 07:21

1. 2.7 — Plain-language glosses restored: Added the ER’s explanations to “Anticoagulants and antiplatelet drugs” (“blood thinners that slow clotting”) and “Photosensitizing drugs” (“drugs that make skin more sensitive to light”), and glossed “Acromegaly” as “(adult growth hormone excess)” in the Contraindications list.
2. 4.2 — ER bold labels made verbatim: Restored the full ER bold labels for the anticoagulant, photosensitizing-drug, GABA (“a calming brain messenger”) and PRP (“a concentrate of the person’s own platelets”) Key Interactions items.

Issues 28/09/2026 07:18

1. 2.7 — Unexplained “w/w” abbreviation: action_1_sub (line 450) reads “patent range 0.00043–0.00243% w/w sh-Polypeptide-7”, using the technical abbreviation “w/w” without the ER’s plain-language explanation (ingredient weight per product weight).
2. 2.13 — Audience framing dropped: at_a_glance (line 433) omits the ER Conclusion’s audience scope (“For hair-focused adults willing to invest effort, sh-Polypeptide-7 is an add-on…”), presenting the verdict as a general statement rather than one framed for the target audience.

Fixes 28/09/2026 07:18

1. 2.7 — Unexplained “w/w” abbreviation: In action_1_sub, replaced “0.00043–0.00243% w/w sh-Polypeptide-7” with “0.00043–0.00243% sh-Polypeptide-7 by product weight”.
2. 2.13 — Audience framing dropped: Restored the ER Conclusion’s audience scope in at_a_glance (“is, for hair-focused adults willing to invest effort, an add-on…”) and condensed the evidence sentence to “small seller-linked studies without comparison groups” to stay within 70 words.

Issues 28/09/2026 07:15

1. 2.7 — Unexplained specialist terms: “secretagogues” (caution_items, line 558) and “trichoscopy” (monitoring_cadence, line 708) appear without the plain-language glosses the ER provides (“drugs that trigger natural growth hormone release”; “magnified scalp imaging”).

Fixes 28/09/2026 07:15

1. 2.7 — Glossed specialist terms: Added the ER’s plain-language glosses: “secretagogues” now reads “secretagogues (drugs that trigger natural growth hormone release; …)” in caution_items, and “trichoscopy” now reads “trichoscopy (magnified scalp imaging)” in monitoring_cadence.

Issues 28/09/2026 07:12

1. 2.7 — Specialist acronyms left unexpanded: “IGF-1” (Contraindications line 544, Risks line 588), “NSAIDs” (line 561), “GABA” (line 564), and “PRP” (line 566) appear without the plain-language expansions the ER gives, while TSH, CBC, and WADA are expanded.
2. 14.2 — Monitoring biomarkers missing: C-reactive protein and free thyroxine, named in the ER Monitoring table as tests paired with ferritin and TSH (ER lines 321-322), are not listed in the Monitoring table, although CBC from the same context is.

Fixes 28/09/2026 07:12

1. 2.7 — Expanded specialist acronyms: Added the ER’s expansions at first use: “IGF-1 (insulin-like growth factor 1)” in Contraindications, “NSAIDs (nonsteroidal anti-inflammatory drugs; …)”, “GABA [gamma-aminobutyric acid]”, and “PRP [platelet-rich plasma]” in Key Interactions.
2. 14.2 — Added missing monitoring biomarkers: Added Monitoring rows for C-reactive protein (paired with ferritin) and free thyroxine (paired with TSH), matching the ER Monitoring table notes.